Literature DB >> 11020559

Long-term urinary toxicity after 3-dimensional conformal radiotherapy for prostate cancer in patients with prior history of transurethral resection.

A S Sandhu1, M J Zelefsky, H J Lee, D Lombardi, Z Fuks, S A Leibel.   

Abstract

PURPOSE: To report on the long-term urinary morbidity among prostate cancer patients with a prior history of a transurethral resection of the prostate (TURP) treated with high-dose 3-dimensional conformal radiotherapy (3D-CRT). METHODS AND MATERIALS: Between 1988 and 1997, 1100 patients with clinically localized prostate cancer were treated with 3D-CRT. Of these, 120 patients (8%) were identified as having had a prior TURP and are the subjects of this analysis. The median age was 71 years (range: 49-83 years). The clinical stages of the patients were T1c: 33 (28%); T2a: 38 (32%); T2b: 15 (13%); and T3: 34 (27%). Neoadjuvant androgen ablation therapy was given to 39 (33%). The median radiation dose prescribed to the planning target volume was 75.6 Gy (range: 64.8-81 Gy). The median elapsed time from TURP to initiation of 3D-CRT was 69 months (range: 4-360 months). The median follow-up time was 51 months (range: 18-109 months).
RESULTS: Five patients of the 120 with a prior history of TURP (4%) developed a urethral stricture after 3D-CRT which was corrected with dilatation. The 5-year actuarial likelihood of >/= Grade 2 late urinary toxicities was 9%. No Grade 4 urinary toxicities were observed in this group of patients. Among 110 patients who were completely continent of urine prior to 3D-CRT, 10 (9%) developed stress incontinence requiring 1 pad daily for protection or experienced occasional leakage (not requiring pad protection). The 5-year incidence of >/= Grade 1 stress incontinence was 18% in patients who developed acute >/= Grade 2 GU symptoms during the course of 3D-CRT compared to 7% for patients who experienced Grade 1 or no acute urinary symptoms (p = 0.05). The radiation dose (>/=75.6 Gy vs. <75.6 Gy), the number of prior TURP procedures, or the volume of resected tissue at the time of TURP had no significant impact on the long-term urinary morbidity outcome. A multivariate analysis demonstrated that the presence of Grade 2 acute urinary symptoms was the only predictor of >/= Grade 1 stress incontinence after 3D-CRT in this group of patients.
CONCLUSIONS: Despite prior TURP, the incidence of >/= Grade 3 urinary toxicities is low. Nevertheless, especially among patients with a prior history of TURP who experience Grade 2 acute urinary symptoms during radiation treatment, a higher risk of stress incontinence is observed.

Entities:  

Mesh:

Year:  2000        PMID: 11020559     DOI: 10.1016/s0360-3016(00)00714-8

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  14 in total

Review 1.  Combination surgery for erectile dysfunction and male incontinence.

Authors:  Dominic Lee; O Lenaine Westney; Run Wang
Journal:  Curr Urol Rep       Date:  2011-12       Impact factor: 3.092

2.  Can high-dose-rate brachytherapy prevent the major genitourinary complication better than external beam radiation alone for patients with previous transurethral resection of prostate?

Authors:  Hao Lun Luo; Fu Min Fang; Chih Hsiung Kang; Yao Chi Chuang; Po Hui Chiang
Journal:  Int Urol Nephrol       Date:  2012-09-13       Impact factor: 2.370

3.  Severe genitourinary toxicity following radiation therapy for prostate cancer--how long does it last?

Authors:  Sung Kim; Dirk F Moore; Weichung Shih; Yong Lin; Hui Li; Yu-Hsuan Shao; Shunhua Shen; Grace L Lu-Yao
Journal:  J Urol       Date:  2012-11-16       Impact factor: 7.450

4.  Reduced late urinary toxicity with high-dose intensity-modulated radiotherapy using intra-prostate fiducial markers for localized prostate cancer.

Authors:  A Zapatero; M Roch; D Büchser; P Castro; L Fernández-Banda; G Pozo; O Liñán; C Martin de Vidales; A Cruz-Conde; F García-Vicente
Journal:  Clin Transl Oncol       Date:  2017-04-03       Impact factor: 3.405

Review 5.  Management of complications of prostate cancer treatment.

Authors:  M Dror Michaelson; Shane E Cotter; Patricio C Gargollo; Anthony L Zietman; Douglas M Dahl; Matthew R Smith
Journal:  CA Cancer J Clin       Date:  2008-05-23       Impact factor: 508.702

6.  Male urinary incontinence: prevalence, risk factors, and preventive interventions.

Authors:  Tatyana A Shamliyan; Jean F Wyman; Ryan Ping; Timothy J Wilt; Robert L Kane
Journal:  Rev Urol       Date:  2009

7.  The evolution of rectal and urinary toxicity and immune response in prostate cancer patients treated with two three-dimensional conformal radiotherapy techniques.

Authors:  Jana Vranova; Stepan Vinakurau; Jan Richter; Miroslav Starec; Anna Fiserova; Jozef Rosina
Journal:  Radiat Oncol       Date:  2011-07-27       Impact factor: 3.481

8.  Single blind randomized phase III trial to investigate the benefit of a focal lesion ablative microboost in prostate cancer (FLAME-trial): study protocol for a randomized controlled trial.

Authors:  Irene M Lips; Uulke A van der Heide; Karin Haustermans; Emile N J T van Lin; Floris Pos; Stefan P G Franken; Alexis N T J Kotte; Carla H van Gils; Marco van Vulpen
Journal:  Trials       Date:  2011-12-05       Impact factor: 2.279

9.  Morbidity dynamics in proton-photon or photon radiation therapy for locally advanced prostate cancer.

Authors:  Evgeny V Khmelevsky; Irina N Kancheli; Vladimir S Khoroshkov; Andrey D Kaprin
Journal:  Rep Pract Oncol Radiother       Date:  2017-11-24

10.  Urinary functional outcomes and toxicity five years after proton therapy for low- and intermediate-risk prostate cancer: results of two prospective trials.

Authors:  Randal H Henderson; Bradford S Hoppe; Robert B Marcus; William M Mendenhall; R Charles Nichols; Zuofeng Li; Zhong Su; Christopher G Morris; Christopher R Williams; Joseph Costa; Nancy P Mendenhall
Journal:  Acta Oncol       Date:  2013-04       Impact factor: 4.089

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.